The liver disease markers aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), total bilirubin levels and the steatosis marker controlled attenuation parameter (CAP) and liver stiffness per FibroScan were higher in the ALD and NAFLD cohorts compared with controls, respectively (all comparisons were significant, except bilirubin and liver stiffness only had a trend for control vs ALD). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.